Clinical Trial Update: Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating Pyrotinib in combination with Capecitabine for trastuzumab-resistant HER2-positive metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Pyrotinib (pyrotinib)

Snippet

Sponsor: Fudan University | Conditions: Metastatic Breast Cancer | Phase 2 | Status: UNKNOWN